keyword
MENU ▼
Read by QxMD icon Read
search

Relapsed acute lymphoblastic leukemia

keyword
https://www.readbyqxmd.com/read/29675840/outcome-of-children-with-newly-diagnosed-acute-lymphoblastic-leukemia-treated-with-cclg-all-2008-the-first-nation-wide-prospective-multicenter-study-in-china
#1
Lei Cui, Zhi-Gang Li, Yi-Huan Chai, Jie Yu, Ju Gao, Xiao-Fan Zhu, Run-Ming Jin, Xiao-Dong Shi, Le-Ping Zhang, Yi-Jin Gao, Rui-Dong Zhang, Hu-Yong Zheng, Shao-Yan Hu, Ying-Hui Cui, Yi-Ping Zhu, Yao Zou, Margaret Hl Ng, Yan Xiao, Jun-Hui Li, Yong-Hong Zhang, Hai-Long He, Ying Xian, Tian-You Wang, Chi-Kong Li, Min-Yuan Wu
Acute lymphoblastic leukemia (ALL) is the most common malignancy among children. The trial Chinese Children Leukemia Group (CCLG)-ALL 2008 was a prospective clinical trial designed to improve treatment outcome of childhood ALL through the first nation-wide collaborative study in China. Totally 2231 patients were recruited from ten tertiary hospitals in eight cities. The patients were stratified according to clinical-biological characteristics and early treatment response. Standard risk (SR) and intermediate risk (IR) groups were treated with a modified BFM based protocol, and there was 25-50% dose reduction during intensification phases in the SR group...
April 20, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29669823/recurrent-patterns-of-protein-expression-signatures-in-pediatric-acute-lymphoblastic-leukemia-recognition-and-therapeutic-guidance
#2
Fieke W Hoff, Chenyue W Hu, Yihua Qiu, Andrew Ligeralde, Suk-Young Yoo, Eveline Sjm De Bont, Amina A Qutub, Terzah M Horton, Steven M Kornblau
Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and the second leading cause of pediatric cancer death in developed countries. While the cure rate for newly-diagnosed ALL is excellent, the genetic heterogeneity and chemoresistance of leukemia cells at relapse makes individualized curative treatment plans difficult. We hypothesize that genetic events would coalesce into a finite number of protein signatures that could guide the design of individualized therapy. Custom Reverse Phase Protein Arrays were produced from pediatric ALL (n=73) and normal CD34+ (n=10) samples with 194 validated antibodies...
April 18, 2018: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/29668614/arthritis-of-large-joints-shown-as-a-rare-clinical-feature-of-cytokine-release-syndrome-after-chimeric-antigen-receptor-t-cell-therapy-a-case-report
#3
Li-Xin Wang, Xiaoping Chen, Mingming Jia, Shengdian Wang, Jianliang Shen
RATIONALE: Chimeric antigen receptor (CAR)-T cell therapy is a novel type of therapy that is being used in an increasing number of patients with acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is the most common complication following CAR-T treatment, but the current understanding of the clinical manifestations and pathogenesis of CRS is still limited. PATIENT CONCERNS: A 34-year-old male patient was diagnosed with ALL in June 2015. Complete remission (CR) was achieved after induction chemotherapy...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29665944/-current-status-and-challenges-of-car-t-immunotherapy-in-hematologic-malignancies-review
#4
Xin Cheng, Ya-Jie Wang, Shuai Feng, Ya-Yun Wu, Tong-Hua Yang, Xun Lai
The chimeric antigen receptor (CAR) T cell therapy has gradually became a new trend in the treatment of refractory and relapsed hematologic malignancies by developing for 30 years. With the exciting development of genetic engineering, CAR-T technology has subjected to 4 generations of innovation. Structure of CAR-T started from a single signal molecule to 2 or more than 2 co-stimulatory molecules, and then coding the CAR gene or promoter. CAR-T can specifically recognize tumor antigens, and does not be restricted by major histocompatibility complex (MHC), thus making a breakthrough in clinical treatment...
April 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29664513/vitiligo-type-cutaneous-manifestation-of-chronic-graft-versus-host-disease-case-report
#5
Karla Gálvez, Paula Muñoz, Valentina Vera, Claudio Arce
INTRODUCTION: Graft-versus-host disease (GVHD) is caused by a pathologic and destructive response of the organism as a result of the interaction between donor immunocompetent T lymphocytes and the recipient tisular antigens. It's considered the most serious complication of hematopoietic stem cell transplantation, most frequently described after bone marrow transplantation (BMT). The skin is usually the first and most commonly affected organ, in both acute and chronic, with a variable clinical spectrum of presentation...
February 2018: Revista Chilena de Pediatría
https://www.readbyqxmd.com/read/29661787/thromboembolism-in-acute-lymphoblastic-leukemia-results-of-nopho-all2008-protocol-treatment-in-patients-1-45-years
#6
Cecilie Utke Rank, Nina Toft, Ruta Tuckuviene, Kathrine Grell, Ove Juul Nielsen, Thomas Leth Frandsen, Hanne Vibeke Hansen Marquart, Birgitte Klug Albertsen, Ulf Tedgård, Helene Hallböök, Ellen Ruud, Kirsten Brunsvig Jarvis, Petter Quist-Paulsen, Pasi Huttunen, Ulla Wartiovaara-Kautto, Ólafur Gísli Jónsson, Sonata Saulyte Trakymiene, Laimonas Griškevičius, Kadri Saks, Mari Punab, Kjeld Schmiegelow
Thromboembolism frequently occurs during acute lymphoblastic leukemia (ALL) therapy. We prospectively registered thromboembolic events during treatment of 1772 consecutive Nordic/Baltic ALL patients 1-45years treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol (7/2008-4/2017). The 2.5-year cumulative incidence of thromboembolism (N=137) was 7.9% (95% confidence interval (CI) 6.6-9.1); higher in patients ≥10years ( P <.0001). Adjusted hazard ratios (HRa) were associated with greater age (10...
April 16, 2018: Blood
https://www.readbyqxmd.com/read/29651352/prolonged-survival-of-acute-lymphoblastic-leukemia-with-intrathecal-treatments-for-isolated-central-nervous-system-relapse
#7
Elan Gorshein, Sheila Kalathil, Mecide Gharibo
Acute lymphoblastic leukemia is commonly cured when diagnosed in the pediatric population. It portends a poorer prognosis if present in adult patients. Although adults frequently achieve complete remission, relapse rates are substantial, particularly among the elderly and high-risk populations. In the absence of prophylactic intrathecal chemotherapy, more than half of patients may develop CNS involvement or relapse, which is associated with significant risk for systemic illness. This report describes a patient with acute lymphoblastic leukemia with repeated isolated CNS relapses...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/29642462/new-challenges-in-targeting-signaling-pathways-in-acute-lymphoblastic-leukemia-by-ngs-approaches-an-update
#8
REVIEW
Adrián Montaño, Maribel Forero-Castro, Darnel Marchena-Mendoza, Rocío Benito, Jesús María Hernández-Rivas
The identification and study of genetic alterations involved in various signaling pathways associated with the pathogenesis of acute lymphoblastic leukemia (ALL) and the application of recent next-generation sequencing (NGS) in the identification of these lesions not only broaden our understanding of the involvement of various genetic alterations in the pathogenesis of the disease but also identify new therapeutic targets for future clinical trials. The present review describes the main deletions, amplifications, sequence mutations, epigenetic lesions, and new structural DNA rearrangements detected by NGS in B-ALL and T-ALL and their clinical importance for therapeutic procedures...
April 7, 2018: Cancers
https://www.readbyqxmd.com/read/29625246/droplet-digital-pcr-is-a-robust-tool-for-monitoring-minimal-residual-disease-in-adult-philadelphia-positive-acute-lymphoblastic-leukemia
#9
Nicoletta Coccaro, Luisa Anelli, Antonella Zagaria, Paola Casieri, Giuseppina Tota, Paola Orsini, Luciana Impera, Angela Minervini, Crescenzio F Minervini, Cosimo Cumbo, Elisa Parciante, Paola Carluccio, Claudia Brunetti, Giorgina Specchia, Francesco Albano
The BCR-ABL1 p190 fusion transcript (m-bcr) is the most frequent variant observed in Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). Qualitative-PCR and real-time quantitative PCR are the currently used methods to monitor minimal residual disease (MRD) in Ph+ ALL patients; for the latter, full standardization and an international quality validation are lacking. Here, we developed a droplet digital PCR (ddPCR) assay for MRD monitoring in p190+ ALL cases. The analytical performance was assessed by the limit of detection determination, demonstrating a reliability, sensitivity, and precision of the assay of up to 0...
April 3, 2018: Journal of Molecular Diagnostics: JMD
https://www.readbyqxmd.com/read/29608548/reassessment-of-the-risk-stratified-gd-2008-all-protocol
#10
Li-Ping Que, Ke Huang, Jian-Pei Fang, Hong-Gui Xu, Dun-Hua Zhou, Yang Li, Lv-Hong Xu, Jian Li, Hai-Lei Chen
OBJECTIVE: To explore the clinical features and outcomes of relapsed childhood acute lymphoblastic leukemia (ALL) at our center, achieve the early detection of risk factors for recurrence and assess the risk-stratified Guangdong (GD)-2008 ALL protocol. MATERIALS AND METHODS: In total, 59 Chinese childhood ALL patients treated with the GD-2008 ALL protocol who relapsed between July 2008 and March 2015 were enrolled in this study. Their clinical features and outcomes were retrospectively analyzed and compared with those of 218 patients who achieved continuous complete remission...
March 30, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29605883/induction-of-a-central-memory-and-stem-cell-memory-phenotype-in-functionally-active-cd4-and-cd8-car-t-cells-produced-in-an-automated-good-manufacturing-practice-system-for-the-treatment-of-cd19-acute-lymphoblastic-leukemia
#11
Franziska Blaeschke, Dana Stenger, Theresa Kaeuferle, Semjon Willier, Ramin Lotfi, Andrew Didier Kaiser, Mario Assenmacher, Michaela Döring, Judith Feucht, Tobias Feuchtinger
Relapsed/refractory B-precursor acute lymphoblastic leukemia (pre-B ALL) remains a major therapeutic challenge. Chimeric antigen receptor (CAR) T cells are promising treatment options. Central memory T cells (Tcm) and stem cell-like memory T cells (Tscm) are known to promote sustained proliferation and persistence after T-cell therapy, constituting essential preconditions for treatment efficacy. Therefore, we set up a protocol for anti-CD19 CAR T-cell generation aiming at high Tcm/Tscm numbers. 100 ml peripheral blood from pediatric pre-B ALL patients was processed including CD4+ /CD8+ -separation, T-cell activation with modified anti-CD3/-CD28 reagents and transduction with a 4-1BB-based second generation CAR lentiviral vector...
March 31, 2018: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29603593/phase-i-trial-of-the-mtor-inhibitor-everolimus-in-combination-with-multi-agent-chemotherapy-in-relapsed-childhood-acute-lymphoblastic-leukemia
#12
Andrew E Place, Yana Pikman, Kristen E Stevenson, Marian H Harris, Melinda Pauly, Maria-Luisa Sulis, Nobuko Hijiya, Lia Gore, Todd M Cooper, Mignon L Loh, Giovanni Roti, Donna S Neuberg, Sarah K Hunt, Sarah Orloff-Parry, Kimberly Stegmaier, Stephen E Sallan, Lewis B Silverman
BACKGROUND: We sought to determine the feasibility of co-administering everolimus with a four-drug reinduction in children and adolescents with acute lymphoblastic leukemia (ALL) experiencing a first marrow relapse. PROCEDURE: This phase I study tested everolimus with vincristine, prednisone, pegaspargase and doxorubicin in patients with marrow relapse occurring >18 months after first complete remission (CR). The primary aim was to identify the maximum tolerated dose of everolimus...
March 30, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29603337/cxcr4-blockade-improves-leukemia-eradication-by-allogeneic-lymphocyte-infusion
#13
Chun-Hui Jin, Yang Li, Jinxing Xia, Yuying Li, Mo Chen, Zheng Hu, Markus Y Mapara, Wei Li, Yong-Guang Yang
Persistent low levels of disease in bone marrow, an immunoprivileged tissue, are responsible for relapse following allogeneic hematopoietic cell transplantation. Using mouse models carrying primary human acute lymphoblast leukemia derived from MLL-AF9-overexpressing human hematopoietic stem cells, we demonstrate that allogeneic lymphocyte infusion (ALI)-mediated graft-vs.-leukemia effects selectively spare leukemia cells in the bone marrow. The resistance of leukemia cells to ALI within bone marrow is due to the immunosuppressive status of the tissue, as ALI achieved a significantly increased complete remission rate when leukemia cells were dislodged from bone marrow by treatment with a CXCR4 antagonist AMD3100...
March 30, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29603136/anti-thymocyte-globulin-improves-survival-free-from-relapse-and-graft-versus-host-disease-after-allogeneic-peripheral-blood-stem-cell-transplantation-in-patients-with-philadelphia-negative-acute-lymphoblastic-leukemia-an-analysis-by-the-acute-leukemia-working
#14
Tomasz Czerw, Myriam Labopin, Sebastian Giebel, Gérard Socié, Liisa Volin, Nathalie Fegueux, Tamás Masszi, Didier Blaise, Sridhar Chaganti, Jan J Cornelissen, Jakob Passweg, Johan Maertens, Maija Itälä-Remes, Depei Wu, Mohamad Mohty, Arnon Nagler
BACKGROUND: Mobilized peripheral blood stem cells are currently the predominant source of grafts for allogeneic transplantation (allogeneic peripheral blood stem cell transplantation [allo-PBSCT]), although, in comparison with bone marrow, their use is associated with an increased risk of chronic graft-versus-host disease (cGVHD). Attempts to reduce the incidence of cGVHD include the addition of anti-thymocyte globulin (ATG) to the pretransplant conditioning regimen. METHODS: The goal of this retrospective study was to analyze the effect of ATG on allo-PBSCT outcomes for adults with Philadelphia-negative acute lymphoblastic leukemia (Ph-neg ALL)...
March 30, 2018: Cancer
https://www.readbyqxmd.com/read/29577208/hematopoietic-stem-cell-transplantation-for-adult-philadelphia-negative-acute-lymphoblastic-leukemia-in-the-first-complete-remission-in-the-era-of-minimal-residual-disease
#15
REVIEW
Christianne Bourlon, Dennis Lacayo-Leñero, Sergio I Inclán-Alarcón, Roberta Demichelis-Gómez
PURPOSE OF REVIEW: The purpose of this review is to discuss the potential role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for Philadelphia-negative (Ph- ) adult acute lymphoblastic leukemia (ALL) in first complete remission (CR1) in the era of minimal residual disease (MRD). RECENT FINDINGS: Allo-HSCT continues to have a role in the therapy of a selected group of high-risk adult patients with ALL in CR1. Although the clinical significance of MRD has been studied less extensively in adults with ALL than in children, recent studies support its role as the strongest prognostic factor that can identify patients that are unlikely to be cured by standard chemotherapy and benefit from undergoing allo-HSCT...
March 26, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29575541/simultaneous-detection-of-abl1-mutation-and-ikzf1-deletion-in-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-using-a-customized-target-enrichment-system-panel
#16
M Aoe, H Ishida, T Matsubara, S Karakawa, H Kawaguchi, K Fujiwara, K Kanamitsu, K Washio, K Okada, M Shibakura, A Shimada
INTRODUCTION: Recent clinical outcomes of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) vastly improved owing to tyrosine kinase inhibitor (TKI). However, the genetic status would be different in each case with ABL1 gene mutation or copy number variants (CNVs) such as IKZF1 deletion. In particular, the TKI resistant clone with ABL1 kinase mutation remains problematic. The comprehensive assessment of genetic status including mutation, insertion and deletion (indel) and CNVs is necessary...
March 25, 2018: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/29574915/cyclophosphamide-versus-etoposide-in-combination-with-total-body-irradiation-as-conditioning-regimen-for-adult-patients-with-ph-negative-acute-lymphoblastic-leukemia-undergoing-allogeneic-stem-cell-transplant-on-behalf-of-the-alwp-of-the-ebmt
#17
Anna Czyz, Myriam Labopin, Sebastian Giebel, Gerard Socié, Jane Apperley, Liisa Volin, Péter Reményi, Ibrahim Yakoub-Agha, Kim Orchard, Mauricette Michallet, Gernot Stuhler, Sridhar Chaganti, Martin Murray, Mahmoud Aljurf, Adrian Bloor, Jacob Passweg, Jürgen Finke, Mohamad Mohty, Arnon Nagler
Allogeneic hematopoietic cell transplantation (alloHCT) with myeloablative conditioning based on total body irradiation (TBI) is widely used for the treatment of adults with acute lymphoblastic leukemia (ALL). TBI is most frequently administered in combination with either cyclophosphamide (Cy/TBI) or etoposide (Vp/TBI). The goal of this study was to retrospectively compare these two regimens. Adult patients with Ph-negative ALL treated with alloHCT in first or second complete remission who received Cy/TBI (n=1346) or Vp/TBI (n=152) conditioning were included in the analysis...
March 25, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29574396/comparison-of-intensive-pediatric-inspired-therapy-with-non-intensive-therapy-in-older-adults-aged-55-65-years-with-philadelphia-chromosome-negative-acute-lymphoblastic-leukemia
#18
Josep-Maria Ribera, Olga García, Cristina Gil, Santiago Mercadal, Irene García-Cadenas, Pau Montesinos, Pere Barba, Susana Vives, José González-Campos, Mar Tormo, Jordi Esteve, Aurelio López, María José Moreno, Jordi Ribera, Natalia Alonso, Arancha Bermúdez, María Luz Amigo, Eulàlia Genescà, Daniel García, Ferran Vall-Llovera, Juan Miguel Bergua, Ramon Guàrdia, María Carmen Monteserín, Teresa Bernal, María Calbacho, María Pilar Martínez, Evarist Feliu
BACKGROUND AND OBJECTIVE: The standardization of treatment of older adults with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) is challenging, especially in the age range of 55-65 years. This study aimed to compare intensive, pediatric-inspired therapy with non-intensive therapy in this population of patients. PATIENTS AND METHODS: The outcomes of 67 patients prospectively included in two consecutive pediatric-inspired intensive protocols (ALL-HR03 and ALL-HR11) from the Spanish PETHEMA Group were compared with those from 44 patients included in a contemporary semi-intensive protocol (ALL-OLD07)...
March 19, 2018: Leukemia Research
https://www.readbyqxmd.com/read/29574283/vs-5584-as-a-pi3k-mtor-inhibitor-enhances-apoptotic-effects-of-subtoxic-dose-arsenic-trioxide-via-inhibition-of-nf-%C3%AE%C2%BAb-activity-in-b-cell-precursor-acute-lymphoblastic-leukemia
#19
Bahareh Toosi, Farhad Zaker, Fatemeh Alikarami, Ahmad Kazemi, Majid Teremmahi Ardestanii
Activation of the phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway as a survival signaling cascade is a prominent feature of cancers such as acute lymphoblastic leukemia (ALL). In patients with B-cell precursor-ALL (BCP-ALL), the high activity of the pathway correlates with the weak response to anti-leukemic drugs and relapse as a result of downstream prosurvival pathway activation, such as nuclear factor kappa B (NF-κB). Recent targeted therapy (PI3K/mTOR inhibitors) in combination with a multifunctional conventional chemotherapeutic drug may be useful for treatment of BCP-ALL patients...
March 22, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29572111/comparative-analysis-of-flow-cytometry-and-rq-pcr-for-the-detection-of-minimal-residual-disease-in-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-after-hematopoietic-stem-cell-transplantation
#20
Xiangyu Zhao, Xiaosu Zhao, Huan Chen, Yazhen Qin, Lanping Xu, Xiaohui Zhang, Kaiyan Liu, Xiaojun Huang, Yingjun Chang
The aim of this study was to examine the value of MRD detection by multiparameter flow cytometry (MFC) and RQ-PCR at the early stage after hematopoietic stem cell transplantation (HSCT) for predicting relapse and leukemia-free survival (LFS) in Philadelphia chromosome-positive ALL (Ph+-ALL). Patients who maintained complete molecular remission (CMR, BCR/ABL<0.01%) status at 1 and 3 months were associated with a lower relapse rate (P=0.02 and <0.001) and better LFS (P=0.014 and 0.013) than those without a CMR...
March 20, 2018: Biology of Blood and Marrow Transplantation
keyword
keyword
18112
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"